Across TCGA pan-cancer cohorts, C11orf97 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C11orf97 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher C11orf97 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C11orf97 expression acts as an unfavorable survival marker.
SARC are the cancer types where C11orf97 Mutation most reproducibly stratifies survival.